Shares of Sellas Life Sciences (SLS) dropped to $12.03, down 6.0%, as traders continue to jostle for position ahead of what could be the most consequential data readout in the company's history: the final survival analysis of its late-stage leukemia trial. With no revenue, a stock up 175% this year, and options activity heavily skewed toward bullish bets, the pullback underscores how fragile sentiment becomes when an entire company's value hinges on a single clinical result.
• Two Deaths Away From a Make-or-Break Moment. Sellas's contract research organization reported that 78 of the required 80 patient deaths — the events that trigger the final analysis — had occurred as of May 11.
As of a July 9 update, no official press release or SEC filing confirms the 80th event has been reached.
Once it does, the company will lock its database, conduct a blinded review, run the statistics, then unblind and disclose whether the therapy helped leukemia patients in remission live longer. A positive result could support a regulatory filing; a negative one could collapse the stock.
• Heavy Call Bets Signal Conviction — and Risk. Recent options data show call volume of roughly 11,679 contracts against just 3,193 puts, yielding a put-to-call ratio of 0.27 — a strongly bullish tilt. That lopsided positioning means if trial data disappoint, the unwind could be violent. Alliance Global recently raised its price target to $25 from $10 , but such targets are meaningless until data arrive. The stock's whipsaw — up 16.8% one day, down 11% the next in recent weeks — reflects a market trading headlines, not fundamentals.
• Cash Buys Time, but the Burn Is Real. Sellas held $107.1 million in cash as of March 31 and collected another $7.5 million from warrant exercises in Q2.
But R&D spending rose to $5.1 million from $3.2 million a year ago, and the quarterly net loss widened to $8.4 million.
A $150 million at-the-market stock-selling facility has been set up but not yet used — a dilution lever management can pull if the trial succeeds and it needs to fund commercialization.
• The CEO's Quiet-Period Signal Adds Urgency. CEO Angelos Stergiou said in a July 9 LinkedIn post that it "may likely be my last brief posting around REGAL before we approach the critical 80th event" and enter a quiet period.
He argued that the slow pace of patient deaths could actually reflect the drug working , but that interpretation remains unproven until the data are unblinded. For shareholders, the next few weeks are binary: either the trial validates a potential first-in-class leukemia therapy — or it doesn't.